Partnering with TGV-Inhalonix

TGV-inhalonix is dedicated to the development of inhaled Mul-1867 to treat lung infections in cystic fibrosis patients. As a research-based and innovation-driven company, we devote our science to deepening the understanding of pathological processes and uncovering new approaches to the development of life-saving drugs.  We believe that we can best achieve these goals together with partners who can supplement and complement our strengths and capabilities.

If you are interested in partnering with us in the development of this promising drug candidate, please contact us at tets@tgvlabs.com

TGV-inhalonix has successful partnerships involving companies, funds and academic institutions. Here are some examples of our partnerships.

Tufts_University_logo  Копия-logo-e1446663486736

 

nyu         ts-logo